Press Release

Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth

28 April 2021
  • U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
  • Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ (Zeta-BC-003)
  • Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions

April 28, 2021 – (Syracuse, New York) - Zetagen Therapeutics, Inc. a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions today announced that the European Patent Office issued Patent. No. 3148517 to the Company. The patent, entitled Composition and Methods to Promote Bone Formation, covers the use of methods for stimulating bone growth using its small molecule, ZetaMet™ (Zeta-BC-003). ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier.

The European patent follows the previously issued Australian Patent. No. 2015267006, U.S. Patent. No. 10208306 and South African PCT. 201700029 covering the use of a method for stimulating bone growth using a small molecule and U.S. Patent Nos. 102656437 covering the use of methods to promote controlled bone creation and destruction as a means to repair large bone segmental defects.

“I am pleased with both our Clinical and IP Global progress to bring our novel technologies to the worldwide market, so patients suffering from painful metastatic lesions have access to our products”, said Joe C. Loy, CEO Zetagen Therapeutics, Inc.

The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions. Zetagen exclusively licensed its platform technology from the State University of New York in 2016.

All News

About zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs.

The company's pipeline encompasses several oncological candidates targeting metastatic and primary cancers for breast, lung, brain, prostate, and sarcomas with such drugs as ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005).

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Source: Zetagen Therapeutics, Inc.
SUNY Biotech Accelerator
841 E Fayette Street, Suite 1100
Syracuse, NY 13210
Investor Inquiries:
Zetagen Therapeutics, Inc.

Media Inquiries:
Mog & Springer Communications on Behalf of Zetagen Therapeutics, Inc.
Elizabeth Harness, Principal
Phone: +1-585-435-7379